Integra LifeSciences (NASDAQ:IART – Get Free Report) issued its quarterly earnings results on Monday. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.01, Briefing.com reports. Integra LifeSciences had a return on equity of 13.95% and a net margin of 1.51%. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same period in the previous year, the company posted $0.71 earnings per share. The company’s quarterly revenue was up 9.7% compared to the same quarter last year.
Integra LifeSciences Stock Down 1.5 %
NASDAQ:IART opened at $25.03 on Wednesday. The stock’s fifty day moving average price is $29.67 and its two-hundred day moving average price is $33.52. Integra LifeSciences has a 52-week low of $22.36 and a 52-week high of $46.09. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.35 and a current ratio of 4.68. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 50.06, a P/E/G ratio of 1.12 and a beta of 1.11.
Insiders Place Their Bets
In other news, Chairman Stuart Essig acquired 52,641 shares of Integra LifeSciences stock in a transaction on Thursday, May 23rd. The shares were purchased at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares in the company, valued at $13,900,897.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 3.10% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Analysis on Integra LifeSciences
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
- Five stocks we like better than Integra LifeSciences
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- How to Invest in Insurance Companies: A Guide
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- Using the MarketBeat Dividend Tax Calculator
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.